Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

NCT04519983 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Stage IV

Interventions

DRUG: Aumolertinib Oral Tablet

Sponsor

Shanghai Cancer Hospital, China